ACELYRIN, Inc.
ACELYRIN, Inc. (SLRN): 3 pipeline candidates · ~13 mo cash runway · 5 clinical trials. Updated within the last hour.
BioSniper Score
4-factor signal · derived from public data
13.1 months
D/E 0.07 · 0% dilution
Lead: Phase 2
3 candidates
N/A
N/A
A transparent, data-derived signal for ACELYRIN, Inc.across cash runway, pipeline maturity & breadth, catalyst momentum and clinical/regulatory footprint. Each factor traces to tracked public filings — not an investment recommendation.
Key Financials
Market Cap
—
Cash
$58.8M
Quarterly Burn
$39.0M
Runway
13.1 mo
Revenue
—
Cash Runway vs Catalysts
Tracked catalysts land within the current projected cash runway.
Pipeline (3 candidates)
| Drug | Phase |
|---|---|
| izokibep | Phase 2 |
| lonigutamab | Phase 1/Phase 2 |
| slrn-517 | Preclinical |
Frequently asked questions
How many drug candidates are in ACELYRIN, Inc.'s pipeline?
ACELYRIN, Inc. (SLRN) has 3 pipeline candidates tracked by BioSniper across SEC filings and clinical trial registrations.
What is ACELYRIN, Inc.'s lead drug candidate?
ACELYRIN, Inc.'s most advanced tracked candidate is izokibep (Phase 2) for Hidradenitis Suppurativa; Psoriatic Arthritis.
What is ACELYRIN, Inc.'s cash runway?
Based on its most recent reported cash balance and quarterly burn rate, ACELYRIN, Inc. has approximately 13.1 months of cash runway.
Who is the CEO of ACELYRIN, Inc.?
Gloucester Pharmaceuticals Inc is the chief executive officer of ACELYRIN, Inc. (SLRN).
Get the full picture on ACELYRIN, Inc.
Deep pipeline analysis, financial trends, AI-powered investment signals, and real-time catalyst alerts.